Connor, Clark & Lunn Investment Management Ltd. Akebia Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 1,180,759 shares of AKBA stock, worth $3.66 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,180,759

Previous 969,834 21.75%

Holding current value

$3.66 Million

Previous $1.86 Million 130.77%

% of portfolio

0.02%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	BUY	$1.55 - $3.97 $326,933 - $837,372	210,925 Added 21.75%	1,180,759 $4.3 Million
Q1 2025 May 12, 2025	SELL	$1.69 - $2.84 $96,434 - $162,056	-57,062 Reduced 5.56%	969,834 $1.86 Million
Q4 2024 Feb 10, 2025	SELL	$1.26 - $2.13 $24,941 - $42,163	-19,795 Reduced 1.89%	1,026,896 $1.91 Million
Q3 2024 Nov 08, 2024	BUY	$0.94 - $1.55 $594 - $979	632 Added 0.06%	1,046,691 $1.38 Million
Q2 2024 Aug 09, 2024	BUY	$0.86 - $1.63 $1,365 - $2,588	1,588 Added 0.15%	1,046,059 $1.07 Million
Q1 2024 May 09, 2024	BUY	$1.27 - $2.24 $538,673 - $950,100	424,152 Added 68.38%	1,044,471 $1.91 Million
Q4 2023 Feb 09, 2024	SELL	$0.8 - $1.28 $3,058 - $4,893	-3,823 Reduced 0.61%	620,319 $769,000
Q3 2023 Nov 13, 2023	BUY	$0.87 - $1.84 $8,059 - $17,045	9,264 Added 1.51%	624,142 $711,000
Q2 2023 Aug 10, 2023	BUY	$0.51 - $1.43 $159,069 - $446,018	311,901 Added 102.95%	614,878 $565,000
Q1 2023 May 09, 2023	BUY	$0.56 - $1.15 $102,437 - $210,362	182,924 Added 152.37%	302,977 $169,000
Q4 2022 Feb 10, 2023	SELL	$0.25 - $0.58 $97,512 - $226,228	-390,049 Reduced 76.46%	120,053 $69,000
Q3 2022 Nov 10, 2022	BUY	$0.3 - $0.46 $84,999 - $130,332	283,332 Added 124.94%	510,102 $161,000
Q2 2022 Aug 05, 2022	SELL	$0.32 - $0.67 $78,371 - $164,090	-244,911 Reduced 51.92%	226,770 $80,000
Q1 2022 May 12, 2022	BUY	$0.72 - $2.93 $49,870 - $202,946	69,265 Added 17.21%	471,681 $339,000
Q4 2021 Feb 10, 2022	SELL	$2.26 - $3.34 $63,856 - $94,371	-28,255 Reduced 6.56%	402,416 $909,000
Q3 2021 Nov 12, 2021	BUY	$2.35 - $3.88 $515,545 - $851,198	219,381 Added 103.83%	430,671 $1.24 Million
Q2 2021 Aug 12, 2021	BUY	$2.83 - $4.2 $341,391 - $506,658	120,633 Added 133.07%	211,290 $801,000
Q1 2021 May 13, 2021	BUY	$2.92 - $5.06 $264,718 - $458,724	90,657 New	90,657 $307,000
Q4 2017 Feb 09, 2018	SELL	$14.24 - $19.59 $195,871 - $269,460	-13,755 Closed	0 $0
Q3 2017 Nov 14, 2017	SELL	$13.06 - $19.67 $392,387 - $590,985	-30,045 Reduced 68.6%	13,755 $271,000
Q2 2017 Aug 14, 2017	BUY	N/A	43,800	43,800 $629,000

Others Institutions Holding AKBA

# of Institutions

170

Shares Held

106M

Call Options Held

134K

Put Options Held

262K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $570M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Akebia Therapeutics, Inc. Transaction History